External beam radiation therapy for recurrent or residual thyroid cancer: What is the best treatment time and the best candidate for long‐term local disease control?

Introduction Cervical disease control might be challenging in advanced thyroid cancer (DTC). Indications for cervical external beam radiation therapy (EBRT) are controversial. Purpose To identify clinical and molecular factors associated with control of cervical disease with EBRT. Methods Retrospect...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck Vol. 46; no. 6; pp. 1340 - 1350
Main Authors: Cavalcante, Lara Bessa Campelo Pinheiro, Treistman, Natalia, Gonzalez, Fabiola Maria Teresa Torres, Fernandes, Pollyanna Iemini Weyll, Alves Junior, Paulo Alonso Garcia, Andrade, Fernanda Accioly, Ferreira, Elisa Napolitano, Brito, Tarcisio Fontenele De, Pane, Attilio, Corbo, Rossana, Erlich, Felipe, Bulzico, Daniel Alves, Vaisman, Fernanda
Format: Journal Article
Language:English
Published: Hoboken, USA John Wiley & Sons, Inc 01-06-2024
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Introduction Cervical disease control might be challenging in advanced thyroid cancer (DTC). Indications for cervical external beam radiation therapy (EBRT) are controversial. Purpose To identify clinical and molecular factors associated with control of cervical disease with EBRT. Methods Retrospective evaluation and molecular analysis of the primary tumor DTC patients who underwent cervical EBRT between 1995 and 2022 was performed. Results Eighty adults, median age of 61 years, were included. T4 disease was present in 43.7%, lymph node involvement in 42.5%, and distant metastasis in 47.5%. Those with cervical progression were older (62.5 vs. 57.3, p = 0.04) with more nodes affected (12.1 vs. 2.8, p = 0.04) and had EBRT performed later following surgery (76.6 vs. 64 months, p = 0.05). EBRT associated with multikinase inhibitors showed longer overall survival than EBRT alone (64.3 vs. 37.9, p = 0.018) and better local disease control. Performing EBRT before radioiodine (RAI) was associated with longer cervical progression‐free survival (CPFS) than was RAI before (67.5 vs. 34.5, p < 0.01). EBRT ≥2 years after surgery was associated with worse CPFS (4.9 vs. 34, p = 0.04). The most common molecular alterations were ERBB2, BRAF, FAT1, RET and ROS1 and TERT mutation was predictive of worse disease control after EBRT (p = 0.04). Conclusion Younger patients, with fewer affected nodes and treated earlier after surgery had better cervical disease control. Combination of EBRT with MKI improved OS. TERT mutation might indicate worse responders to EBRT; however, further studies are necessary to clarify the role of molecular testing in selecting candidates for cervical EBRT.
AbstractList Introduction Cervical disease control might be challenging in advanced thyroid cancer (DTC). Indications for cervical external beam radiation therapy (EBRT) are controversial. Purpose To identify clinical and molecular factors associated with control of cervical disease with EBRT. Methods Retrospective evaluation and molecular analysis of the primary tumor DTC patients who underwent cervical EBRT between 1995 and 2022 was performed. Results Eighty adults, median age of 61 years, were included. T4 disease was present in 43.7%, lymph node involvement in 42.5%, and distant metastasis in 47.5%. Those with cervical progression were older (62.5 vs. 57.3, p = 0.04) with more nodes affected (12.1 vs. 2.8, p = 0.04) and had EBRT performed later following surgery (76.6 vs. 64 months, p = 0.05). EBRT associated with multikinase inhibitors showed longer overall survival than EBRT alone (64.3 vs. 37.9, p = 0.018) and better local disease control. Performing EBRT before radioiodine (RAI) was associated with longer cervical progression‐free survival (CPFS) than was RAI before (67.5 vs. 34.5, p < 0.01). EBRT ≥2 years after surgery was associated with worse CPFS (4.9 vs. 34, p = 0.04). The most common molecular alterations were ERBB2, BRAF, FAT1, RET and ROS1 and TERT mutation was predictive of worse disease control after EBRT (p = 0.04). Conclusion Younger patients, with fewer affected nodes and treated earlier after surgery had better cervical disease control. Combination of EBRT with MKI improved OS. TERT mutation might indicate worse responders to EBRT; however, further studies are necessary to clarify the role of molecular testing in selecting candidates for cervical EBRT.
IntroductionCervical disease control might be challenging in advanced thyroid cancer (DTC). Indications for cervical external beam radiation therapy (EBRT) are controversial.PurposeTo identify clinical and molecular factors associated with control of cervical disease with EBRT.MethodsRetrospective evaluation and molecular analysis of the primary tumor DTC patients who underwent cervical EBRT between 1995 and 2022 was performed.ResultsEighty adults, median age of 61 years, were included. T4 disease was present in 43.7%, lymph node involvement in 42.5%, and distant metastasis in 47.5%. Those with cervical progression were older (62.5 vs. 57.3, p = 0.04) with more nodes affected (12.1 vs. 2.8, p = 0.04) and had EBRT performed later following surgery (76.6 vs. 64 months, p = 0.05). EBRT associated with multikinase inhibitors showed longer overall survival than EBRT alone (64.3 vs. 37.9, p = 0.018) and better local disease control. Performing EBRT before radioiodine (RAI) was associated with longer cervical progression‐free survival (CPFS) than was RAI before (67.5 vs. 34.5, p < 0.01). EBRT ≥2 years after surgery was associated with worse CPFS (4.9 vs. 34, p = 0.04). The most common molecular alterations were ERBB2, BRAF, FAT1, RET and ROS1 and TERT mutation was predictive of worse disease control after EBRT (p = 0.04).ConclusionYounger patients, with fewer affected nodes and treated earlier after surgery had better cervical disease control. Combination of EBRT with MKI improved OS. TERT mutation might indicate worse responders to EBRT; however, further studies are necessary to clarify the role of molecular testing in selecting candidates for cervical EBRT.
Cervical disease control might be challenging in advanced thyroid cancer (DTC). Indications for cervical external beam radiation therapy (EBRT) are controversial. To identify clinical and molecular factors associated with control of cervical disease with EBRT. Retrospective evaluation and molecular analysis of the primary tumor DTC patients who underwent cervical EBRT between 1995 and 2022 was performed. Eighty adults, median age of 61 years, were included. T4 disease was present in 43.7%, lymph node involvement in 42.5%, and distant metastasis in 47.5%. Those with cervical progression were older (62.5 vs. 57.3, p = 0.04) with more nodes affected (12.1 vs. 2.8, p = 0.04) and had EBRT performed later following surgery (76.6 vs. 64 months, p = 0.05). EBRT associated with multikinase inhibitors showed longer overall survival than EBRT alone (64.3 vs. 37.9, p = 0.018) and better local disease control. Performing EBRT before radioiodine (RAI) was associated with longer cervical progression-free survival (CPFS) than was RAI before (67.5 vs. 34.5, p < 0.01). EBRT ≥2 years after surgery was associated with worse CPFS (4.9 vs. 34, p = 0.04). The most common molecular alterations were ERBB2, BRAF, FAT1, RET and ROS1 and TERT mutation was predictive of worse disease control after EBRT (p = 0.04). Younger patients, with fewer affected nodes and treated earlier after surgery had better cervical disease control. Combination of EBRT with MKI improved OS. TERT mutation might indicate worse responders to EBRT; however, further studies are necessary to clarify the role of molecular testing in selecting candidates for cervical EBRT.
Cervical disease control might be challenging in advanced thyroid cancer (DTC). Indications for cervical external beam radiation therapy (EBRT) are controversial.INTRODUCTIONCervical disease control might be challenging in advanced thyroid cancer (DTC). Indications for cervical external beam radiation therapy (EBRT) are controversial.To identify clinical and molecular factors associated with control of cervical disease with EBRT.PURPOSETo identify clinical and molecular factors associated with control of cervical disease with EBRT.Retrospective evaluation and molecular analysis of the primary tumor DTC patients who underwent cervical EBRT between 1995 and 2022 was performed.METHODSRetrospective evaluation and molecular analysis of the primary tumor DTC patients who underwent cervical EBRT between 1995 and 2022 was performed.Eighty adults, median age of 61 years, were included. T4 disease was present in 43.7%, lymph node involvement in 42.5%, and distant metastasis in 47.5%. Those with cervical progression were older (62.5 vs. 57.3, p = 0.04) with more nodes affected (12.1 vs. 2.8, p = 0.04) and had EBRT performed later following surgery (76.6 vs. 64 months, p = 0.05). EBRT associated with multikinase inhibitors showed longer overall survival than EBRT alone (64.3 vs. 37.9, p = 0.018) and better local disease control. Performing EBRT before radioiodine (RAI) was associated with longer cervical progression-free survival (CPFS) than was RAI before (67.5 vs. 34.5, p < 0.01). EBRT ≥2 years after surgery was associated with worse CPFS (4.9 vs. 34, p = 0.04). The most common molecular alterations were ERBB2, BRAF, FAT1, RET and ROS1 and TERT mutation was predictive of worse disease control after EBRT (p = 0.04).RESULTSEighty adults, median age of 61 years, were included. T4 disease was present in 43.7%, lymph node involvement in 42.5%, and distant metastasis in 47.5%. Those with cervical progression were older (62.5 vs. 57.3, p = 0.04) with more nodes affected (12.1 vs. 2.8, p = 0.04) and had EBRT performed later following surgery (76.6 vs. 64 months, p = 0.05). EBRT associated with multikinase inhibitors showed longer overall survival than EBRT alone (64.3 vs. 37.9, p = 0.018) and better local disease control. Performing EBRT before radioiodine (RAI) was associated with longer cervical progression-free survival (CPFS) than was RAI before (67.5 vs. 34.5, p < 0.01). EBRT ≥2 years after surgery was associated with worse CPFS (4.9 vs. 34, p = 0.04). The most common molecular alterations were ERBB2, BRAF, FAT1, RET and ROS1 and TERT mutation was predictive of worse disease control after EBRT (p = 0.04).Younger patients, with fewer affected nodes and treated earlier after surgery had better cervical disease control. Combination of EBRT with MKI improved OS. TERT mutation might indicate worse responders to EBRT; however, further studies are necessary to clarify the role of molecular testing in selecting candidates for cervical EBRT.CONCLUSIONYounger patients, with fewer affected nodes and treated earlier after surgery had better cervical disease control. Combination of EBRT with MKI improved OS. TERT mutation might indicate worse responders to EBRT; however, further studies are necessary to clarify the role of molecular testing in selecting candidates for cervical EBRT.
Author Andrade, Fernanda Accioly
Alves Junior, Paulo Alonso Garcia
Brito, Tarcisio Fontenele De
Corbo, Rossana
Ferreira, Elisa Napolitano
Pane, Attilio
Vaisman, Fernanda
Treistman, Natalia
Gonzalez, Fabiola Maria Teresa Torres
Bulzico, Daniel Alves
Erlich, Felipe
Cavalcante, Lara Bessa Campelo Pinheiro
Fernandes, Pollyanna Iemini Weyll
Author_xml – sequence: 1
  givenname: Lara Bessa Campelo Pinheiro
  surname: Cavalcante
  fullname: Cavalcante, Lara Bessa Campelo Pinheiro
  organization: Universidade Federal do Rio de Janeiro
– sequence: 2
  givenname: Natalia
  surname: Treistman
  fullname: Treistman, Natalia
  organization: Universidade Federal do Rio de Janeiro
– sequence: 3
  givenname: Fabiola Maria Teresa Torres
  surname: Gonzalez
  fullname: Gonzalez, Fabiola Maria Teresa Torres
  organization: Instituto Nacional de Câncer
– sequence: 4
  givenname: Pollyanna Iemini Weyll
  surname: Fernandes
  fullname: Fernandes, Pollyanna Iemini Weyll
  organization: Instituto Nacional de Câncer
– sequence: 5
  givenname: Paulo Alonso Garcia
  surname: Alves Junior
  fullname: Alves Junior, Paulo Alonso Garcia
  organization: Instituto Nacional de Câncer
– sequence: 6
  givenname: Fernanda Accioly
  surname: Andrade
  fullname: Andrade, Fernanda Accioly
  organization: Instituto Nacional de Câncer
– sequence: 7
  givenname: Elisa Napolitano
  surname: Ferreira
  fullname: Ferreira, Elisa Napolitano
  organization: Grupo Fleury
– sequence: 8
  givenname: Tarcisio Fontenele De
  surname: Brito
  fullname: Brito, Tarcisio Fontenele De
  organization: Universidade Federal do Rio de Janeiro
– sequence: 9
  givenname: Attilio
  surname: Pane
  fullname: Pane, Attilio
  organization: Universidade Federal do Rio de Janeiro
– sequence: 10
  givenname: Rossana
  surname: Corbo
  fullname: Corbo, Rossana
  organization: Instituto Nacional de Câncer
– sequence: 11
  givenname: Felipe
  surname: Erlich
  fullname: Erlich, Felipe
  organization: Instituto Nacional de Câncer
– sequence: 12
  givenname: Daniel Alves
  surname: Bulzico
  fullname: Bulzico, Daniel Alves
  organization: Instituto Nacional de Câncer
– sequence: 13
  givenname: Fernanda
  orcidid: 0000-0002-6835-7108
  surname: Vaisman
  fullname: Vaisman, Fernanda
  email: vaismanfe@gmail.com
  organization: Instituto Nacional de Câncer
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38445804$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1u1DAUhS3Uiv7AghdAltjAIq3_kjhsKlSGtlIlNiCWlmPfMK4Se7Adwex4BN6C9-JJcGZaIVVi5Wv7O-de-5ygAx88IPSCkjNKCDtfgz1jbUvYE3RMSddWhIv2YKkFrzhpxRE6SemOEMIbwZ6iIy6FqCURx-j36keG6PWIe9ATjto6nV3wOK8h6s0WDyHiCGaOEXzGu01ydi6CvN7G4Cw22huIb_GXtc7YpUVZzFLGOYLO0yLLbgKsvf13V0TWWZ1h12AM_uufn7_KJFOpTTG3LoFOgE3wOYbx4hk6HPSY4Pn9eoo-f1h9uryubj9e3Vy-u60Mp5xVneh5eVw7MNn1kjZNb2gzNNJSKcAM0HNDjQVrjOCUdtDXLat1X0tgvTaG8lP0eu-7ieHbXCZVk0sGxlF7CHNSrOOyeFO2oK8eoXdhXr4yKU5qLruSCCnUmz1lYkgpwqA20U06bhUlaklPlfTULr3Cvrx3nPupnD6QD3EV4HwPfHcjbP_vpK5X7_eWfwGSGKkf
Cites_doi 10.1016/j.ijrobp.2021.05.006
10.1002/hed.24513
10.1002/hed.27025
10.1530/ETJ‐21‐0033
10.1089/thy.2018.0214
10.1089/thy.2015.0020
10.1210/jc.2013‐2383
10.1016/s0936‐6555(03)00162‐6
10.1007/s12020‐023‐03300‐2
10.1002/(SICI)1097-0142(19980115)82:2<389::AID-CNCR19>3.0.CO;2-V
10.6004/jnccn.2022.0040
10.1210/jc.2013‐3734
10.1016/0360‐3016(95)00060‐C
10.1038/onc.2013.446
10.1210/jc.2014‐3242
10.1016/j.ejca.2008.10.026
10.1002/hed.24218
10.1007/s10147‐019‐01591‐y
10.1016/j.amjoto.2005.05.017
10.14338/IJPT‐D‐20‐00053
10.1111/cen.14865
10.1002/hed.26133
10.1002/(SICI)1097‐0142(19960101)77:1<172::AID‐CNCR28>3.0.CO;2‐1
10.1677/erc.1.01320
10.1159/000444393
10.1001/jamaoto.2017.2077
10.1016/j.ijrobp.2005.12.010
10.1002/cncr.33804
10.1016/j.cell.2014.09.050
10.1016/j.ijrobp.2008.09.023
10.1038/s41598‐020‐64635‐8
10.1111/j.1365‐2265.2005.02358.x
10.1002/hed.24357
10.1007/978-3-319-40618-3_73
ContentType Journal Article
Copyright 2024 Wiley Periodicals LLC.
Copyright_xml – notice: 2024 Wiley Periodicals LLC.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7TK
K9.
7X8
DOI 10.1002/hed.27702
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList
ProQuest Health & Medical Complete (Alumni)
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1097-0347
EndPage 1350
ExternalDocumentID 10_1002_hed_27702
38445804
HED27702
Genre researchArticle
Journal Article
GrantInformation_xml – fundername: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  funderid: E_10/2016E
– fundername: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  grantid: E_10/2016E
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
36B
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DUUFO
EBD
EBS
EJD
EMB
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M6P
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
V2E
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WWO
WXI
WXSBR
X7M
XG1
XPP
XV2
ZGI
ZXP
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
CITATION
7QP
7TK
K9.
7X8
ID FETCH-LOGICAL-c3132-94b33847f289b8166bc16f68d184ecfeb3c1cdedcc43119eb5725ab58e2bacc13
IEDL.DBID 33P
ISSN 1043-3074
1097-0347
IngestDate Sat Oct 26 04:11:49 EDT 2024
Sun Nov 17 08:43:33 EST 2024
Fri Nov 22 03:10:52 EST 2024
Sat Nov 02 12:13:51 EDT 2024
Sat Aug 24 00:57:03 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords external beam radiation
thyroid cancer
radiation therapy
cervical disease
Language English
License 2024 Wiley Periodicals LLC.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3132-94b33847f289b8166bc16f68d184ecfeb3c1cdedcc43119eb5725ab58e2bacc13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-6835-7108
PMID 38445804
PQID 3053897700
PQPubID 996355
PageCount 11
ParticipantIDs proquest_miscellaneous_2938289121
proquest_journals_3053897700
crossref_primary_10_1002_hed_27702
pubmed_primary_38445804
wiley_primary_10_1002_hed_27702_HED27702
PublicationCentury 2000
PublicationDate June 2024
2024-Jun
2024-06-00
20240601
PublicationDateYYYYMMDD 2024-06-01
PublicationDate_xml – month: 06
  year: 2024
  text: June 2024
PublicationDecade 2020
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
– name: Houston
PublicationTitle Head & neck
PublicationTitleAlternate Head Neck
PublicationYear 2024
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 1995; 31
2009; 45
2023; 98
2021; 8
2018; 28
2020; 42
2006; 13
2015; 100
2021; 127
2005; 63
2003; 15
2022; 20
2022; 44
1998; 82
2020; 10
2016; 38
2014; 159
2023; 80
1996; 77
2009; 74
2016; 90
2013; 98
2006; 65
2006; 27
2017
2020; 25
2021; 111
2022; 11
2017; 143
2016; 26
2014; 33
2014; 99
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_11_1
e_1_2_10_32_1
e_1_2_10_31_1
e_1_2_10_30_1
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 38
  start-page: 1862
  issue: 12
  year: 2016
  end-page: 1869
  article-title: Comprehensive management of recurrent thyroid cancer: an American head and neck society consensus statement
  publication-title: Head Neck
– volume: 159
  start-page: 676
  issue: 3
  year: 2014
  end-page: 690
  article-title: Integrated genomic characterization of papillary thyroid carcinoma
  publication-title: Cell
– volume: 63
  start-page: 418
  issue: 4
  year: 2005
  end-page: 427
  article-title: Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years
  publication-title: Clin Endocrinol (Oxf)
– volume: 80
  start-page: 589
  issue: 3
  year: 2023
  end-page: 599
  article-title: Propensity score matching analysis of adjuvant external‐beam radiotherapy for the treatment of papillary thyroid carcinoma with other organ invasions
  publication-title: Endocrine
– volume: 42
  start-page: 2181
  issue: 8
  year: 2020
  end-page: 2193
  article-title: The role of postoperative external beam radiotherapy for differentiated thyroid carcinoma: a systematic review and meta‐analysis
  publication-title: Head Neck
– volume: 65
  start-page: 474
  issue: 2
  year: 2006
  end-page: 480
  article-title: The role of postoperative external‐beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 44
  start-page: 1277
  issue: 6
  year: 2022
  end-page: 1300
  article-title: American head and neck society endocrine surgery section and international thyroid oncology group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment
  publication-title: Head Neck
– volume: 38
  start-page: E2297
  issue: Suppl 1
  year: 2016
  end-page: E2305
  article-title: External beam radiotherapy in differentiated thyroid carcinoma: a systematic review
  publication-title: Head Neck
– volume: 11
  issue: 1
  year: 2022
  article-title: Postoperative external beam radiotherapy for locoregional control in iodine refractory differentiated thyroid cancer
  publication-title: Eur Thyroid J
– volume: 8
  start-page: 311
  issue: 1
  year: 2021
  end-page: 318
  article-title: Initial experience with proton beam therapy for differentiated thyroid cancer
  publication-title: Int J Part Ther
– volume: 10
  start-page: 8031
  issue: 1
  year: 2020
  article-title: Molecular profile of locally aggressive well differentiated thyroid cancers
  publication-title: Sci Rep
– volume: 98
  start-page: 803
  issue: 6
  year: 2023
  end-page: 812
  article-title: Effect of postoperative radiotherapy for patients with differentiated thyroid cancer
  publication-title: Clin Endocrinol (Oxf)
– volume: 143
  start-page: 1244
  issue: 12
  year: 2017
  end-page: 1251
  article-title: Adjuvant external beam radiotherapy in locally advanced differentiated thyroid cancer
  publication-title: JAMA Otolaryngol Head Neck Surg
– volume: 33
  start-page: 4978
  issue: 42
  year: 2014
  end-page: 4984
  article-title: The age‐ and shorter telomere‐dependent TERT promoter mutation in follicular thyroid cell‐derived carcinomas
  publication-title: Oncogene
– volume: 15
  start-page: 337
  issue: 6
  year: 2003
  end-page: 341
  article-title: External beam radiotherapy in the management of differentiated thyroid cancer
  publication-title: Clin Oncol (R Coll Radiol)
– volume: 127
  start-page: 4161
  issue: 22
  year: 2021
  end-page: 4170
  article-title: Intensity‐modulated radiation therapy and doxorubicin in thyroid cancer: a prospective phase 2 trial
  publication-title: Cancer
– volume: 98
  start-page: E1562
  issue: 9
  year: 2013
  end-page: E1566
  article-title: Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease
  publication-title: J Clin Endocrinol Metab
– volume: 27
  start-page: 24
  issue: 1
  year: 2006
  end-page: 28
  article-title: External beam radiotherapy for differentiated thyroid cancer
  publication-title: Am J Otolaryngol
– volume: 99
  start-page: E754
  issue: 5
  year: 2014
  end-page: E765
  article-title: TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas
  publication-title: J Clin Endocrinol Metab
– volume: 77
  start-page: 172
  issue: 1
  year: 1996
  end-page: 180
  article-title: Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4)
  publication-title: Cancer
– volume: 82
  start-page: 375
  issue: 2
  year: 1998
  end-page: 388
  article-title: The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma
  publication-title: Cancer
– volume: 90
  start-page: 209
  issue: 4
  year: 2016
  end-page: 214
  article-title: The role of adjuvant radiation therapy for locoregionally advanced papillary thyroid carcinoma
  publication-title: Oncology
– volume: 26
  start-page: 1
  issue: 1
  year: 2016
  end-page: 133
  article-title: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer
  publication-title: Thyroid
– volume: 111
  start-page: 468
  issue: 2
  year: 2021
  end-page: 478
  article-title: External beam radiation therapy in pT4 well‐differentiated thyroid cancer: a population‐based study of 405 patients
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 31
  start-page: 1341
  issue: 5
  year: 1995
  end-page: 1346
  article-title: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 38
  start-page: 493
  issue: 4
  year: 2016
  end-page: 498
  article-title: External‐beam radiotherapy for differentiated thyroid cancer locoregional control: a statement of the American head and neck society
  publication-title: Head Neck
– volume: 74
  start-page: 1083
  issue: 4
  year: 2009
  end-page: 1091
  article-title: Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment
  publication-title: Int J Radiat Oncol Biol Phys
– year: 2017
– volume: 28
  start-page: 1180
  issue: 9
  year: 2018
  end-page: 1189
  article-title: Intensity‐modulated radiation therapy with or without concurrent chemotherapy in nonanaplastic thyroid cancer with unresectable or gross residual disease
  publication-title: Thyroid
– volume: 25
  start-page: 691
  issue: 4
  year: 2020
  end-page: 697
  article-title: Treatment intensity and control rates in combining external‐beam radiotherapy and radioactive iodine therapy for metastatic or recurrent differentiated thyroid cancer
  publication-title: Int J Clin Oncol
– volume: 20
  start-page: 925
  issue: 8
  year: 2022
  end-page: 951
  article-title: Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology
  publication-title: J Natl Compr Canc Netw
– volume: 13
  start-page: 1159
  issue: 4
  year: 2006
  end-page: 1172
  article-title: Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition
  publication-title: Endocr Relat Cancer
– volume: 100
  start-page: 1009
  issue: 3
  year: 2015
  end-page: 1017
  article-title: Postoperative simultaneous integrated boost‐intensity modulated radiation therapy for patients with locoregionally advanced papillary thyroid carcinoma: preliminary results of a phase II trial and propensity score analysis
  publication-title: J Clin Endocrinol Metab
– volume: 45
  start-page: 228
  issue: 2
  year: 2009
  end-page: 247
  article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  publication-title: Eur J Cancer
– ident: e_1_2_10_13_1
  doi: 10.1016/j.ijrobp.2021.05.006
– ident: e_1_2_10_3_1
  doi: 10.1002/hed.24513
– ident: e_1_2_10_2_1
  doi: 10.1002/hed.27025
– ident: e_1_2_10_19_1
  doi: 10.1530/ETJ‐21‐0033
– ident: e_1_2_10_35_1
  doi: 10.1089/thy.2018.0214
– ident: e_1_2_10_4_1
  doi: 10.1089/thy.2015.0020
– ident: e_1_2_10_31_1
  doi: 10.1210/jc.2013‐2383
– ident: e_1_2_10_24_1
  doi: 10.1016/s0936‐6555(03)00162‐6
– ident: e_1_2_10_26_1
  doi: 10.1007/s12020‐023‐03300‐2
– ident: e_1_2_10_12_1
  doi: 10.1002/(SICI)1097-0142(19980115)82:2<389::AID-CNCR19>3.0.CO;2-V
– ident: e_1_2_10_6_1
  doi: 10.6004/jnccn.2022.0040
– ident: e_1_2_10_34_1
  doi: 10.1210/jc.2013‐3734
– ident: e_1_2_10_15_1
  doi: 10.1016/0360‐3016(95)00060‐C
– ident: e_1_2_10_32_1
  doi: 10.1038/onc.2013.446
– ident: e_1_2_10_27_1
  doi: 10.1210/jc.2014‐3242
– ident: e_1_2_10_16_1
  doi: 10.1016/j.ejca.2008.10.026
– ident: e_1_2_10_7_1
  doi: 10.1002/hed.24218
– ident: e_1_2_10_22_1
  doi: 10.1007/s10147‐019‐01591‐y
– ident: e_1_2_10_18_1
  doi: 10.1016/j.amjoto.2005.05.017
– ident: e_1_2_10_29_1
  doi: 10.14338/IJPT‐D‐20‐00053
– ident: e_1_2_10_21_1
  doi: 10.1111/cen.14865
– ident: e_1_2_10_9_1
  doi: 10.1002/hed.26133
– ident: e_1_2_10_10_1
  doi: 10.1002/(SICI)1097‐0142(19960101)77:1<172::AID‐CNCR28>3.0.CO;2‐1
– ident: e_1_2_10_11_1
  doi: 10.1677/erc.1.01320
– ident: e_1_2_10_20_1
  doi: 10.1159/000444393
– ident: e_1_2_10_23_1
  doi: 10.1001/jamaoto.2017.2077
– ident: e_1_2_10_8_1
  doi: 10.1016/j.ijrobp.2005.12.010
– ident: e_1_2_10_28_1
  doi: 10.1002/cncr.33804
– ident: e_1_2_10_30_1
  doi: 10.1016/j.cell.2014.09.050
– ident: e_1_2_10_25_1
  doi: 10.1016/j.ijrobp.2008.09.023
– ident: e_1_2_10_33_1
  doi: 10.1038/s41598‐020‐64635‐8
– ident: e_1_2_10_17_1
  doi: 10.1111/j.1365‐2265.2005.02358.x
– ident: e_1_2_10_5_1
  doi: 10.1002/hed.24357
– ident: e_1_2_10_14_1
  doi: 10.1007/978-3-319-40618-3_73
SSID ssj0003642
Score 2.4683366
Snippet Introduction Cervical disease control might be challenging in advanced thyroid cancer (DTC). Indications for cervical external beam radiation therapy (EBRT)...
Cervical disease control might be challenging in advanced thyroid cancer (DTC). Indications for cervical external beam radiation therapy (EBRT) are...
IntroductionCervical disease control might be challenging in advanced thyroid cancer (DTC). Indications for cervical external beam radiation therapy (EBRT) are...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 1340
SubjectTerms Adult
Aged
cervical disease
Disease control
ErbB-2 protein
external beam radiation
Female
Humans
Iodine Radioisotopes - therapeutic use
Lymph nodes
Male
Metastases
Middle Aged
Mutation
Neoplasm Recurrence, Local
Neoplasm, Residual
Patients
Radiation therapy
Retrospective Studies
Surgery
Survival
Thyroid cancer
Thyroid Neoplasms - mortality
Thyroid Neoplasms - pathology
Thyroid Neoplasms - radiotherapy
Thyroidectomy
Thyroxine
Time Factors
Title External beam radiation therapy for recurrent or residual thyroid cancer: What is the best treatment time and the best candidate for long‐term local disease control?
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhed.27702
https://www.ncbi.nlm.nih.gov/pubmed/38445804
https://www.proquest.com/docview/3053897700
https://www.proquest.com/docview/2938289121
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LSsUwEA3qyo0PfNUXo7hwU71J05cuRPTKXYmggrvSPKqC9krrXbjzE_wL_8svcSbtrYgIgruWpE2bmcmcSTInjO3EXCqE7dYPjcwxQIkCPzVoV0URJJGx6MAcffHgMj6_SU77RJNzOM6Fafghugk3sgw3XpOB56re_yINvbNmT8SxI5LEKMGlbwQX3SgcRLJZ6ZQBza_IMatQT-x3T373RT8A5ne86hzO2ey_PnWOzbQ4E44bxZhnE7ZcYO_9lvMZlM0foSJeAhIMNFlYL4AIFiqagSfOJnA3tcvWwhov1fDegCYtqQ6AKL_hvqYn8WX1M3Q71oGOq4e8NF9lmnJnaGrBNfAwLG8_Xt_IJ4BzpdCuEkG7b_5okV2f9a9OBn57UoOvifrRT6XCUFfGBYZvilYileZRESUG40erCwzYNdfGGq0Rr_DUqjAWYa7CxAqVa82DJTZVDku7wiBN8zRWScK5tdKIXmpkGBfahloLZZLCY9tjmWVPDSFH1lAviwz7OXP97LH1sTSz1ibrDEc2RGdY3PPYVleM1kRLJHlph6M6Q_BDISgX3GPLjRZ0reAPyjDpSY_tOmH_3nw26J-6i9W_V11j0wLxUrMLbZ1NPVcju8EmazPadIr9CdYx_Sw
link.rule.ids 315,782,786,1408,27934,27935,46065,46489
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB5BOcCFH_EXaGFAHLiErh0ncVAlhOhWiygVEkXiZsU_oZVKFiXdQ288Am_Be_EkzDjZVBVCQuKWyE6c2DOeb8aezwDPSqEswfaQ5l7V5KAUWVp50qumyXThAxmwSF-8-FgefNa7c6bJ2Vnnwgz8EFPAjTUjztes4ByQ3j5nDT0K_oUsS2aSvKIKpVmms-zDNA9nhRrWOlXGERa15hWaye3p0YvW6A-IeRGxRpOzd-P_PvYmXB-hJr4eZOMWXArtbfg5H2mf0Yb6K3ZMTcBjg0Mi1hkSiMWOg_BM24Txpo8JW1TjrFsee3QsKN1LZNZvPO75SXpZf4rTpnXkE-uxbv15meP0GY4uxAZOlu2XX99_sFnAaE1xXCjCcev8qzvwaW9--GaRjoc1pI7ZH9NKWfJ2VdmQB2d5MdI6UTSF9uRCBteQz-6E88E7R5BFVMHmpcxrm-sgbe2cyO7CRrtsw33Aqqqr0motRAjKy1nlVV42LuTOSet1k8DT9aCZbwMnhxnYl6WhfjaxnxPYXA-nGdWyNzS5EUCj4lkCT6ZiUiheJanbsFz1hvAPe6FCigTuDWIwtUI_qHI9Uwk8j6P99-bNYr4bLx78e9XHcHVx-H7f7L89ePcQrkmCT8OmtE3YOO1WYQsu9371KEr5b8SuAWQ
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BkRAXHuIVKGWKOPQSunacFxyqqrurrUBVJYrEzYofKZUgWyXdQ2_8BP4F_4tfwoyTTVUhJCRuiezEiT3j-cae-QzwOhfKEGz3cepURQ5KlsSlI72q66TInCcDFuiLFx_zo8_FdMY0Oe_WuTA9P8S44MaaEeZrVvBzV-9ekYZ-8e6NzHMmkrylCIZzPF-SHI_TcJKpfqtTJbzAota0QhO5Oz563Rj9gTCvA9Zgceb3_utb78PdAWjifi8ZD-CGbx7Cz9lA-ozGV9-wZWICHhns07AukSAstrwEz6RNGG66kK5FNS7b5ZlDy2LSvkXm_Mazjp-kl3UXOIasI59Xj1XjrsosJ8_w2kJo4OuyOf31_QcbBQy2FIdtIhwC5_cewaf57ORgEQ9HNcSWuR_jUhnydVVek_9meCvSWJHVWeHIgfS2Jo_dCuu8s5YAiyi9SXOZViYtvDSVtSJ5DBvNsvFPAcuyKnNTFEJ4r5yclE6leW19aq00rqgjeLUeM33eM3LonntZaupnHfo5gs31aOpBKTtNUxvBMyqeRLA9FpM68R5J1fjlqtOEftgHFVJE8KSXgrEV-kGVFhMVwU4Y7L83rxezabh49u9VX8Lt4-lcfzg8ev8c7kjCTn1E2iZsXLQr_wJudm61FWT8N646AAo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=External+beam+radiation+therapy+for+recurrent+or+residual+thyroid+cancer%3A+What+is+the+best+treatment+time+and+the+best+candidate+for+long%E2%80%90term+local+disease+control%3F&rft.jtitle=Head+%26+neck&rft.au=Cavalcante%2C+Lara+Bessa+Campelo+Pinheiro&rft.au=Treistman%2C+Natalia&rft.au=Gonzalez%2C+Fabiola+Maria+Teresa+Torres&rft.au=Fernandes%2C+Pollyanna+Iemini+Weyll&rft.date=2024-06-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1043-3074&rft.eissn=1097-0347&rft.volume=46&rft.issue=6&rft.spage=1340&rft.epage=1350&rft_id=info:doi/10.1002%2Fhed.27702&rft.externalDBID=10.1002%252Fhed.27702&rft.externalDocID=HED27702
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-3074&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-3074&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-3074&client=summon